Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025

MT Newswires Live

01/30

Shenzhen Hepalink Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.

Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.

The company's financial results are due by the end of March.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2607019353"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607019353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607019353?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607019353","market":"sh","top_or_hot":-1,"title":"Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SHEZF\">Shenzhen Hepalink</a> Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.</p><p>Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.</p><p>The company's financial results are due by the end of March.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-30 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SHEZF\">Shenzhen Hepalink</a> Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.</p><p>Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.</p><p>The company's financial results are due by the end of March.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09989","symbol_name":"海普瑞","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2607019353","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607019353","pubTimestamp":1769768436,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shenzhen Hepalink Pharmaceutical Group  said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.The company's financial results are due by the end of March.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09989":"海普瑞","BK1191":"制药"},"translate_title":"深圳海普瑞预计2025年利润最多下降56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09989":1},"content_text":"Shenzhen Hepalink Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.The company's financial results are due by the end of March.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}